COMPARATIVE STUDY OF DOVATO vs TAF-CONTAINING REGIMENS IN MORE THAN 700 VIROLOGICALLY SUPPRESSED PATIENTS
Phase III, Randomised, Multicentre, Parallel-Group, Non-Inferiority Switch Study 1
CONFIDENCE WITH POWERFUL EFFICACY MAINTAINED AT WEEK 48
No Increased Risk of Virological Failure vs TAF-Containing Regimens 1‡
ITT–E Snapshot analysis.
REASSURANCE WITH A HIGH BARRIER TO RESISTANCE UP TO 48 WEEKS
§Patients met confirmed virological withdrawal criteria if they had 1 assessment with HIV-1 RNA ≥200 copies/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 copies/mL
- van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO study). Presented at: International AIDS Conference; July 21-24, 2019; Mexico City. Slides WEAB0403LB.
- Dovato Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last Accessed, June 2020.